Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protocadherin-1 deficiency increases baseline and allergen-induced airway hyperresponsiveness in mice.

American journal of respiratory cell and molecular biology·2026
Same author

The Ste20 kinase TAOK3 restrains Rac-driven cytoskeletal-mitochondrial coupling to preserve naive CD8<sup>+</sup> T cell homeostasis and activation.

Frontiers in immunology·2026
Same author

Endothelial cells notch monocytes toward an alveolar macrophage fate.

The Journal of experimental medicine·2026
Same author

POLY-Senolytic nanoplatform for tumor-specific eradication of senescent tumor cells and mitigation of radiotherapy-induced immune resistance of cancer.

Nature communications·2026
Same author

Spatiotemporal Nanotransformers for Antitumoral Orchestration of Protein Homeostasis.

Polymer science & technology (Washington, D.C.)·2026
Same author

In honor of Prof. Véronique Préat.

Drug delivery and translational research·2026

Related Experiment Video

Updated: Nov 19, 2025

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.8K

Lipid-Polyglutamate Nanoparticle Vaccine Platform.

Dorien Van Lysebetten1, Alessio Malfanti2, Kim Deswarte3

  • 1Department of Pharmaceutics, Ghent University, 9000 Ghent, Belgium.

ACS Applied Materials & Interfaces
|January 28, 2021
PubMed
Summary

A novel lipid nanoparticle (LNP) platform enables co-delivery of peptide antigens and molecular adjuvants. This strategy enhances innate immune cell uptake and promotes robust T cell responses for advanced vaccine development.

Keywords:
TLR agonistslipid nanoparticlespeptidesvaccine

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.8K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.4K

Related Experiment Videos

Last Updated: Nov 19, 2025

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
08:07

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

2.8K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.8K
Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

1.4K

Area of Science:

  • Vaccinology
  • Immunology
  • Nanotechnology

Background:

  • Peptide-based vaccines, including those for personalized cancer therapy and infectious diseases, require efficient delivery to antigen-presenting cells.
  • Co-delivery of peptide antigens and molecular adjuvants is crucial for robust, antigen-specific immunity.
  • Current methods face challenges in co-encapsulating diverse peptide antigens and molecular adjuvants due to differing physicochemical properties.

Purpose of the Study:

  • To develop a versatile lipid nanoparticle (LNP) platform for co-delivering peptide antigens and molecular adjuvants.
  • To overcome limitations in encapsulating molecules with varied properties for enhanced vaccine design.

Main Methods:

  • A platform utilizing poly(l-glutamic acid) (PGA) as a backbone for conjugating peptide antigens (Ag) and imidazoquinoline (IMDQ) TLR7/8 agonists.
  • Condensation of PGA-Ag and PGA-IMDQ into LNPs via electrostatic interaction with an ionizable lipid.
  • In vitro and in vivo evaluation in mouse models to assess immune cell uptake and T cell responses.

Main Results:

  • The developed LNP platform successfully co-encapsulates peptide antigens and molecular adjuvants.
  • LNPs demonstrated enhanced uptake by innate immune cells within lymphoid tissues.
  • Significant induction of antigen-specific T cell responses was observed following both subcutaneous and intravenous administration in mouse models.

Conclusions:

  • The novel LNP platform provides a generic strategy for co-delivering peptide antigens and molecular adjuvants.
  • This approach effectively enhances antigen presentation and T cell immunity, paving the way for next-generation vaccines.
  • The platform holds promise for personalized cancer vaccines and vaccines against infectious diseases.